WONCA研究论文摘要汇编——利福昔明治疗肝性脑病

发布时间：2018-03-27 11:23

  本文选题：急性肝性脑病　切入点：利福昔明　出处：《中国全科医学》2010年33期

【摘要】：正【摘要】背景肝性脑病是肝硬化的慢性衰竭并发症。利福昔明属吸收量极微的抗生素,其治疗急性肝性脑病有良好的证据,但其预防疾病的效果尚未确定。方法随机、双盲、安慰剂对照试验,将299例因慢性肝病导致肝性脑病反复发作的患者随机分组:利福昔明组140例,接
[Abstract]:Background Hepatic encephalopathy is a complication of chronic failure of liver cirrhosis. Rifaximin is an antibiotic with minimal absorption and has good evidence for the treatment of acute hepatic encephalopathy. In a placebo controlled trial, 299 patients with recurrent hepatic encephalopathy due to chronic liver disease were randomly divided into two groups: rifaximin group, 140 patients, followed by
【作者单位】： 中国石油中心医院;
【分类号】：R747.9
，

本文编号：1671305